$28.97 Million in Sales Expected for Agios Pharmaceuticals Inc (NASDAQ:AGIO) This Quarter

Equities analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to announce $28.97 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Agios Pharmaceuticals’ earnings, with the highest sales estimate coming in at $31.99 million and the lowest estimate coming in at $27.10 million. Agios Pharmaceuticals reported sales of $15.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 90.6%. The firm is expected to issue its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $116.41 million for the current financial year, with estimates ranging from $110.00 million to $122.98 million. For the next year, analysts expect that the firm will report sales of $152.72 million, with estimates ranging from $112.00 million to $186.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). The company had revenue of $26.22 million during the quarter, compared to analyst estimates of $27.05 million. Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. Agios Pharmaceuticals’s revenue was down 35.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.19) earnings per share.

Several equities analysts have weighed in on the company. BidaskClub cut Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 27th. Guggenheim raised Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Monday, September 23rd. BMO Capital Markets assumed coverage on Agios Pharmaceuticals in a report on Thursday, September 12th. They issued an “outperform” rating and a $45.00 price objective for the company. Zacks Investment Research cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating and set a $40.00 price objective for the company. in a report on Monday, September 16th. Finally, Cowen reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $62.43.

NASDAQ AGIO traded down $0.56 during midday trading on Tuesday, hitting $34.16. The company had a trading volume of 517,529 shares, compared to its average volume of 537,057. The company has a market capitalization of $1.97 billion, a PE ratio of -5.67 and a beta of 2.31. The company has a current ratio of 5.96, a quick ratio of 5.91 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average price of $37.47 and a 200-day moving average price of $48.46. Agios Pharmaceuticals has a twelve month low of $31.46 and a twelve month high of $74.25.

Several institutional investors and hedge funds have recently modified their holdings of AGIO. BlackRock Inc. grew its position in Agios Pharmaceuticals by 30.8% during the 2nd quarter. BlackRock Inc. now owns 4,362,184 shares of the biopharmaceutical company’s stock worth $217,585,000 after acquiring an additional 1,027,819 shares during the last quarter. Invesco Ltd. grew its position in Agios Pharmaceuticals by 66.3% during the 2nd quarter. Invesco Ltd. now owns 1,396,773 shares of the biopharmaceutical company’s stock worth $69,671,000 after acquiring an additional 556,825 shares during the last quarter. First Trust Advisors LP grew its position in Agios Pharmaceuticals by 31.4% during the 1st quarter. First Trust Advisors LP now owns 1,774,158 shares of the biopharmaceutical company’s stock worth $119,649,000 after acquiring an additional 423,931 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in Agios Pharmaceuticals during the 1st quarter worth $23,110,000. Finally, First Light Asset Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth $12,365,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Recommended Story: What is range trading?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.